Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug ...
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin ...
Paris and Tarrytown, NY, April 22, 2026. The US Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of children aged two to 11 years with chronic spontaneous urticaria ...
The U.S. Food and Drug Administration (FDA) on Wednesday delayed its decision on Sanofi SA’s SNY subcutaneous Sarclisa ...
MBX Biosciences targets endocrine and metabolic disorders with novel peptide therapies, advancing candidates across several ...
The trial involved adults and adolescents aged 12 years and above with MOGAD, offering an open-label extension.
Nationwide overnight delivery from Walmart improves access to novel at-home prescription treatment, with particular benefit for rural communities where transportation and distance are often barriers ...
The Dow Jones Industrial Average was established on May 26, 1896, as a straightforward benchmark to monitor market ...
Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.
The FDA has extended its review of a new subcutaneous formulation of Sanofi's multiple myeloma therapy Sarclisa – which has ...
Report OverviewThe global insulin pumps market is projected to grow at a rate of 12% by 2028, fueled by rising diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results